Literature DB >> 10999979

Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function.

C D Frances1, H Noguchi, B M Massie, W S Browner, M McClellan.   

Abstract

CONTEXT: Angiotensin-converting enzyme (ACE) inhibitors have been shown to decrease mortality in patients with myocardial infarction and depressed left ventricular function, but physicians may be reluctant to prescribe ACE inhibitors to patients with concomitant renal insufficiency.
OBJECTIVE: To evaluate whether patients with depressed left ventricular ejection fraction following acute myocardial infarction have a similar reduction in mortality from ACE inhibitors regardless of their renal function.
DESIGN: Retrospective cohort study using medical record data.
SETTING: All nonfederal acute care hospitals. PATIENTS: A cohort of 20,902 Medicare beneficiaries aged 65 years and older directly admitted to the hospital from February 1, 1994, through July 30, 1995, and with a documented left ventricular ejection fraction of less than 40% measured by echocardiography, radionuclide scintigraphy, or angiography following a confirmed acute myocardial infarction. MAIN OUTCOME MEASURES: One-year survival for patients who received or who did not receive an ACE inhibitor at hospital discharge, stratified by the patient's level of renal function.
RESULTS: For the entire cohort, the receipt of an ACE inhibitor on hospital discharge was associated with greater 1-year survival (hazards ratio, 0.84; 95% confidence interval, 0.77-0.91) after adjusting for patient demographic characteristics, comorbidity, severity of illness (including left ventricular ejection fraction), and the receipt of other therapies. In stratified models, the receipt of an ACE inhibitor was associated with a 37% (16%-52%) lower mortality for patients who had poor renal function (serum creatinine level,<265 micromol/L [<3 mg/dL]) and a 16% (8%-23%) lower mortality for patients who had better renal function. Use of aspirin therapy attenuated the benefit of ACE inhibitors in patients with poor renal function.
CONCLUSIONS: Moderate renal insufficiency should not be considered a contraindication to the use of ACE inhibitors in patients with depressed left ventricular ejection fraction following myocardial infarction. Use of aspirin therapy may attenuate the benefit of ACE inhibitors in patients with high serum creatinine levels; therefore, further studies are needed to determine whether treatment with aspirin, alternative antiplatelet agents, or anticoagulation is indicated for these patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10999979     DOI: 10.1001/archinte.160.17.2645

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  16 in total

Review 1.  The contribution of observational studies to the knowledge of drug effectiveness in heart failure.

Authors:  Daniela Dobre; Dirk J van Veldhuisen; Mike J L DeJongste; Eric van Sonderen; Olaf H Klungel; Robbert Sanderman; Adelita V Ranchor; Flora M Haaijer-Ruskamp
Journal:  Br J Clin Pharmacol       Date:  2007-08-31       Impact factor: 4.335

2.  Evidence-based practice guideline for the treatment of CKD.

Authors: 
Journal:  Clin Exp Nephrol       Date:  2009-12       Impact factor: 2.801

3.  Effects of angiotensin-converting enzyme inhibitors in systolic heart failure patients with chronic kidney disease: a propensity score analysis.

Authors:  Ali Ahmed; Thomas E Love; Xuemei Sui; Michael W Rich
Journal:  J Card Fail       Date:  2006-09       Impact factor: 5.712

Review 4.  Can we prevent or treat renal dysfunction in chronic heart failure?

Authors:  Daniela Dobre; Patrick Rossignol; Marco Metra; Faiez Zannad
Journal:  Heart Fail Rev       Date:  2012-03       Impact factor: 4.214

5.  Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study.

Authors:  Ali Ahmed; Michael W Rich; Paul W Sanders; Gilbert J Perry; George L Bakris; Michael R Zile; Thomas E Love; Inmaculada B Aban; Michael G Shlipak
Journal:  Am J Cardiol       Date:  2006-12-08       Impact factor: 2.778

6.  Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease.

Authors:  Ali Ahmed; Gregg C Fonarow; Yan Zhang; Paul W Sanders; Richard M Allman; Donna K Arnett; Margaret A Feller; Thomas E Love; Inmaculada B Aban; Raynald Levesque; O James Ekundayo; Louis J Dell'Italia; George L Bakris; Michael W Rich
Journal:  Am J Med       Date:  2012-02-07       Impact factor: 4.965

7.  Hospital performance and differences by kidney function in the use of recommended therapies after non-ST-elevation acute coronary syndromes.

Authors:  Uptal D Patel; Fang-Shu Ou; E Magnus Ohman; W Brian Gibler; Charles V Pollack; Eric D Peterson; Matthew T Roe
Journal:  Am J Kidney Dis       Date:  2008-12-19       Impact factor: 8.860

8.  Therapies for acute heart failure in patients with reduced kidney function: a community-based perspective.

Authors:  Robert J Goldberg; Rovshan M Ismailov; Vishnu Patlolla; Darleen Lessard; Frederick A Spencer
Journal:  Am J Kidney Dis       Date:  2008-02-07       Impact factor: 8.860

9.  ACE inhibitor and angiotensin II type 1 receptor antagonist therapies in elderly patients with diabetes mellitus: are they underutilized?

Authors:  Lamioko Shika Pappoe; Wolfgang C Winkelmayer
Journal:  Drugs Aging       Date:  2010-02-01       Impact factor: 3.923

10.  Increased mortality among survivors of myocardial infarction with kidney dysfunction: the contribution of gaps in the use of guideline-based therapies.

Authors:  Pamela N Peterson; Amrut V Ambardekar; Philip G Jones; Harlan M Krumholz; Erik Schelbert; John A Spertus; John S Rumsfeld; Frederick A Masoudi
Journal:  BMC Cardiovasc Disord       Date:  2009-07-08       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.